Literature DB >> 7935459

Identification and characterization by antisense oligonucleotides of exon and intron sequences required for splicing.

Z Dominski1, R Kole.   

Abstract

Certain thalassemic human beta-globin pre-mRNAs carry mutations that generate aberrant splice sites and/or activate cryptic splice sites, providing a convenient and clinically relevant system to study splice site selection. Antisense 2'-O-methyl oligoribonucleotides were used to block a number of sequences in these pre-mRNAs and were tested for their ability to inhibit splicing in vitro or to affect the ratio between aberrantly and correctly spliced products. By this approach, it was found that (i) up to 19 nucleotides upstream from the branch point adenosine are involved in proper recognition and functioning of the branch point sequence; (ii) whereas at least 25 nucleotides of exon sequences at both 3' and 5' ends are required for splicing, this requirement does not extend past the 5' splice site sequence of the intron; and (iii) improving the 5' splice site of the internal exon to match the consensus sequence strongly decreases the accessibility of the upstream 3' splice site to antisense 2'-O-methyl oligoribonucleotides. This result most likely reflects changes in the strength of interactions near the 3' splice site in response to improvement of the 5' splice site and further supports the existence of communication between these sites across the exon.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7935459      PMCID: PMC359280          DOI: 10.1128/mcb.14.11.7445-7454.1994

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  48 in total

1.  Exon definition may facilitate splice site selection in RNAs with multiple exons.

Authors:  B L Robberson; G J Cote; S M Berget
Journal:  Mol Cell Biol       Date:  1990-01       Impact factor: 4.272

2.  The length of the downstream exon and the substitution of specific sequences affect pre-mRNA splicing in vitro.

Authors:  P J Furdon; R Kole
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

3.  Exon mutations that affect the choice of splice sites used in processing the SV40 late transcripts.

Authors:  M B Somasekhar; J E Mertz
Journal:  Nucleic Acids Res       Date:  1985-08-12       Impact factor: 16.971

4.  U2 as well as U1 small nuclear ribonucleoproteins are involved in premessenger RNA splicing.

Authors:  D L Black; B Chabot; J A Steitz
Journal:  Cell       Date:  1985-10       Impact factor: 41.582

5.  Identification of exon sequences involved in splice site selection.

Authors:  Z Dominski; R Kole
Journal:  J Biol Chem       Date:  1994-09-23       Impact factor: 5.157

6.  Recognition of cap structure in splicing in vitro of mRNA precursors.

Authors:  M M Konarska; R A Padgett; P A Sharp
Journal:  Cell       Date:  1984-10       Impact factor: 41.582

7.  Normal and mutant human beta-globin pre-mRNAs are faithfully and efficiently spliced in vitro.

Authors:  A R Krainer; T Maniatis; B Ruskin; M R Green
Journal:  Cell       Date:  1984-04       Impact factor: 41.582

8.  beta-Thalassemia in Chinese: use of in vivo RNA analysis and oligonucleotide hybridization in systematic characterization of molecular defects.

Authors:  T C Cheng; S H Orkin; S E Antonarakis; M J Potter; J P Sexton; A F Markham; P J Giardina; A Li; H H Kazazian
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

9.  Cryptic branch point activation allows accurate in vitro splicing of human beta-globin intron mutants.

Authors:  B Ruskin; J M Greene; M R Green
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

10.  Nucleotide substitutions within the cardiac troponin T alternative exon disrupt pre-mRNA alternative splicing.

Authors:  T A Cooper; C P Ordahl
Journal:  Nucleic Acids Res       Date:  1989-10-11       Impact factor: 16.971

View more
  13 in total

1.  Sequences upstream of the branch site are required to form helix II between U2 and U6 snRNA in a trans-splicing reaction.

Authors:  G Ast; T Pavelitz; A M Weiner
Journal:  Nucleic Acids Res       Date:  2001-04-15       Impact factor: 16.971

2.  Sensitivity of splice sites to antisense oligonucleotides in vivo.

Authors:  H Sierakowska; M J Sambade; D Schümperli; R Kole
Journal:  RNA       Date:  1999-03       Impact factor: 4.942

3.  Inverse splicing of a discontinuous pre-mRNA intron generates a circular exon in a HeLa cell nuclear extract.

Authors:  S Braun; H Domdey; K Wiebauer
Journal:  Nucleic Acids Res       Date:  1996-11-01       Impact factor: 16.971

4.  U1 small nuclear RNA-promoted exon selection requires a minimal distance between the position of U1 binding and the 3' splice site across the exon.

Authors:  D Y Hwang; J B Cohen
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

5.  Selection of a nonconsensus branch point is influenced by an RNA stem-loop structure and is important to confer stability to the herpes simplex virus 2-kilobase latency-associated transcript.

Authors:  C Krummenacher; J M Zabolotny; N W Fraser
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

6.  Exon ligation is proofread by the DExD/H-box ATPase Prp22p.

Authors:  Rabiah M Mayas; Hiroshi Maita; Jonathan P Staley
Journal:  Nat Struct Mol Biol       Date:  2006-05-07       Impact factor: 15.369

7.  Effects of splicing mutations on NF2-transcripts: transcript analysis and information theoretic predictions.

Authors:  James R Ellis; Bianca Heinrich; Victor-F Mautner; Lan Kluwe
Journal:  Genes Chromosomes Cancer       Date:  2011-05-11       Impact factor: 5.006

8.  Pre-mRNA topology is important for 3'-end formation in Saccharomyces cerevisiae and mammals.

Authors:  G Stumpf; A Goppelt; H Domdey
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

9.  Advantages of 2'-O-methyl oligoribonucleotide probes for detecting RNA targets.

Authors:  M Majlessi; N C Nelson; M M Becker
Journal:  Nucleic Acids Res       Date:  1998-05-01       Impact factor: 16.971

Review 10.  On future's doorstep: RNA interference and the pharmacopeia of tomorrow.

Authors:  Alan M Gewirtz
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.